Spotlight: Implications of Just Published New PTAB Rules
The use of inter partes review (IPR) to challenge bio/pharma patents has grown significantly — with the number nearly doubling in 2015 alone. While relatively few of them have reached final decisions, what gives some challengers the winning edge?
Please join our experienced attorneys for a discussion on the key challenges you could face with your next IPR, as well as your overall strategies for patent litigation and enforcement, and how to prepare to address them.
Topics include:
- Determining trends based on the first 105+ bio/pharma IPR petitions to be filed
- Discovering the most vulnerable types of bio/pharma patents
- Learning how to prosecute bio/pharma patents to withstand IPR
- Employing tactics to help prevent an institution decision
- Understanding more about biosimilar and biologics-related IPRs
- Reviewing updates on PTAB rule changes
Speakers
Stephen Maebius, Partner, IP Department, Foley & Lardner LLP
Kristel Schorr, Partner and Chair, Chemical, Biotechnology & Pharmaceutical Practice, Foley & Lardner LLP
Moderator
Etsuo Doi, Managing Partner, Tokyo Office, Foley & Lardner LLP
People
Related Insights
22 April 2024
Foley Ignite
AI Regulatory and Legal Issues Today: A Conversation with Natasha Allen
As is the case with most emerging technologies, developments in artificial intelligence are quickly outpacing regulations, and with this comes a variety of important legal considerations.
22 April 2024
Foley Ignite
The Complex Terrain of the Video Game Industry: Challenges and Opportunities
The video game industry is brimming with innovation, competition, and transformative technological advancements.
22 April 2024
Labor & Employment Law Perspectives
Utah Enacts H.B. 55, Impacting the Use of Confidentiality Clauses in Employment Settlement Agreements
On March 13, 2024, Governor Spencer Cox signed House Bill (H.B.) 55 into law, making Utah the latest state to restrict the use of certain nondisclosure and non-disparagement agreements relating to sexual assault or sexual harassment claims.